Last reviewed · How we verify
Anshen Buxin Liuwei Pill — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Anshen Buxin Liuwei Pill (Anshen Buxin Liuwei Pill) — China Academy of Chinese Medical Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anshen Buxin Liuwei Pill TARGET | Anshen Buxin Liuwei Pill | China Academy of Chinese Medical Sciences | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anshen Buxin Liuwei Pill CI watch — RSS
- Anshen Buxin Liuwei Pill CI watch — Atom
- Anshen Buxin Liuwei Pill CI watch — JSON
- Anshen Buxin Liuwei Pill alone — RSS
Cite this brief
Drug Landscape (2026). Anshen Buxin Liuwei Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/anshen-buxin-liuwei-pill. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab